Robbins Geller Announces ImmunityBio Investor Lawsuit Deadline

Investors with substantial losses have opportunity to lead class action lawsuit against ImmunityBio.

Apr. 10, 2026 at 11:36pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life photograph featuring a shattered glass vial or beaker placed on a clean, monochromatic background with dramatic lighting and deep shadows, symbolizing the legal and financial consequences of a biotech company's alleged false statements.A shattered glass vial reflects the broken trust between a biotech company and its investors following allegations of misleading claims.San Diego Today

Robbins Geller Rudman & Dowd LLP has announced a deadline for investors who purchased or acquired ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026 to join a class action lawsuit. The lawsuit alleges that ImmunityBio made false claims about its cancer treatment Anktiva.

Why it matters

This lawsuit represents a significant legal challenge for ImmunityBio, a prominent biotech company, and could have major financial and reputational implications if the allegations are proven true. The outcome of the case could impact investor confidence in ImmunityBio and the broader biotech industry.

The details

The lawsuit alleges that ImmunityBio made misleading statements about its Anktiva cancer treatment, claiming it would allow all non-muscle-invasive bladder cancer (NMIBC) patients to be cancer-free long-term, when this had not been demonstrated. The lawsuit claims these false statements artificially inflated ImmunityBio's stock price during the class period.

  • The class period for the lawsuit is January 19, 2026 to March 24, 2026.
  • The deadline for investors to join the class action lawsuit is April 10, 2026.

The players

Robbins Geller Rudman & Dowd LLP

A law firm that specializes in securities class action lawsuits and has announced the ImmunityBio investor lawsuit.

ImmunityBio, Inc.

A biotechnology company that is facing allegations of making false claims about its Anktiva cancer treatment.

Got photos? Submit your photos here. ›

What’s next

The judge will determine if the lawsuit can proceed as a class action in the coming weeks.

The takeaway

This lawsuit highlights the importance of biotech companies making accurate and transparent claims about their products, as misleading statements can have serious legal and financial consequences. Investors will be closely watching the outcome of this case.